[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"blood-loss-postoperative\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:blood-loss-postoperative":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,48,77],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":31,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":5},"100579264","efficacy-of-intraoperative-arista-polysaccharide-application-on-the-postoperative-blood-loss-in-patients-undergoing-rarp-for-the-treatment-of-prostate-cancer-100579264",false,"NCT06822036","EFFICACY OF INTRAOPERATIVE ARISTA POLYSACCHARIDE APPLICATION ON THE POSTOPERATIVE BLOOD LOSS IN PATIENTS UNDERGOING RARP FOR THE TREATMENT OF PROSTATE CANCER","PROSPECTIVE RANDOMIZED CONTROLLED TRIAL EVALUATING THE EFFICACY OF INTRAOPERATIVE ARISTA™ AH POLYSACCHARIDE APPLICATION ON THE POSTOPERATIVE BLOOD LOSS IN PATIENTS UNDERGOING ROBOTIC ASSISTED RADICAL PROSTATECTOMY FOR THE TREATMENT OF PROSTATE CANCER","ARISTA","Inclusion Criteria:\n\n* Age range ≥ 45 to ≥68 yrs\n* Biopsy proven prostate cancer treated with robotic-assisted radical prostatectomy\n* Intrafascial nerve sparing surgery (unilaterally or bilaterally)\n* Preoperative urinary continence\n* Group A Preoperative unassisted International Index of Erectile function (IIEF)-5 score range 8-16 (i.e. moderate (8-11) and mild to moderate (12-16))\n\nExclusion Criteria:\n\n* Severe intellectual limitations preventing to fully understand the study concept and its content\n* High risk prostate cancer (PSA ≥ 20 ng\u002Fml or biopsy Gleason-Score ≥ 8 or suspected T4)\n* Suspected bone or visceral metastases at preoperative imaging Neoadjuvant androgen deprivation therapy\n* Any prior local therapy of the prostate (including subvesical deobstruction or radiation therapy)\n* Any prior chemotherapy or colon\u002Frectal surgery\n* Any prior pelvic trauma that required surgical intervention\n* Depression or other psychological or neurological disease (dementia, schizophrenia, bipolar disorder etc.)\n* Peyronie's disease\n* Polyneuropathia\n* IPSS Score \\>19 and QoL \\>3\n* Bilateral secondary (complete or partial) resection of the neurovascular bundle\n* No contraindications for phosphodiesterase type 5 inhibitor intake (i.e. suited for most penile rehabilitation regimes)\n* Any endocrine function disorder (not including diabetes)\n\nSURGICAL AND PERIOPERATIVE EXLUSION CRITERIA:\n\n* Accessory pudendal arteries (APA) preservation, if an APA is identified\n* For a) nerve sparing and b) controlling bleeding in the area of the prostate bed and neurovascular bundles after prostate removal, no monopolar thermal application are allowed but suturing and clip application is allowed. For secondary resection of the neurovascular bundle and controlling bleeding, mono- or bipolar thermal application, clip application and suturing is allowed.\n* No surgical revision within 7d after RARP (Clavien Dindo classified complication ≥3b)\n* No definitive anastomotic partial or complete rupture (identified via cystogram within 30d after RARP)","MALE","45 Years","68 Years",{"count":21,"type":22},362,"ESTIMATED","INTERVENTIONAL",[25],"NA","We perform a multicenter randomized controlled prospective study with superiority trial design, in which the polysaccharide ARISTA™ AH hemostat agent is applied to the neurovascular bundle areas after prostate removal, during Robot-assisted radical prostatectomy.\n\nWe examine if such agent leads to a relevant clinical improvement indicated by higher postoperative hemoglobin levels compared to the control group. As an exploratory co-primary endpoint of interest, we examine erectile function after Robot-assisted radical prostatectomy based on IIEF-5 score between groups 3, 6 and 12 months after Robot-assisted radical prostatectomy",[28,29,30],"Prostate Cancer (Adenocarcinoma)","Blood Loss, Postoperative","Erectile Function",[32,33,34,35],"prostate cancer","blood loss","potency rates","ARISTA™ AH","RECRUITING","2026-05-27",{"date":39,"type":40},"2026-05-29","ACTUAL",{"date":42,"type":40},"2025-01-16",{"date":44,"type":22},"2027-01-30",{"name":46,"class":47},"St. Antonius Hospital Gronau","OTHER",{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":4,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":55,"minAge":56,"maxAge":4,"enrollmentInfo":57,"targetDuration":4,"studyType":23,"phases":59,"briefSummary":61,"conditions":62,"keywords":65,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":76},"100609693","phase-2-prophylactic-intravenous-calcium-gluconate-to-decrease-blood-loss-at-time-of-cesarean-delivery-in-pregnant-patients-at-high-risk-for-uterine-atony-100609693","NCT07217899","Prophylactic Intravenous Calcium Gluconate to Decrease Blood Loss at Time of Cesarean Delivery in Pregnant Patients at High Risk for Uterine Atony","Phase II, Randomized, Double Blinded, Placebo Controlled Superiority Trial of Prophylactic Intravenous Calcium Gluconate to Decrease Blood Loss at Time of Cesarean Delivery in Pregnant Patients at High Risk for Uterine Atony","Inclusion Criteria:\n\n* English speaking\n* Viable Intrauterine Pregnancy, Gestational Age ≥24 weeks\n* Labor Converted to Cesarean Delivery at High Risk for Atonic Bleeding Defined as: Any exposure to oxytocin infusion for labor augmentation or induction prior to cesarean delivery\n* Or Scheduled Cesarean Delivery at High Risk for Atonic Bleeding Defined as scheduled Cesarean-Section (CS) plus any one of:\n\n  1. \\> 4 Prior deliveries\n  2. General anesthesia\n  3. Multifetal gestation\n  4. Polyhydramnios diagnosed by ultrasound within 2 weeks\n  5. Macrosomia ≥ 4000gms; estimated fetal weight by palpation or by ultrasound\n  6. Fibroid uterus, defined as: Multiple ≥ 2cm intramural\n  7. Any history of prior Primary postpartum hemorrhage (PPH)\n  8. Platelets \\\u003C 100,000 (but \\>50,000\n  9. Placenta Previa\n  10. Body Mass Index (BMI) ≥ 40\n\nExclusion Criteria:\n\n* Non-English speaking\n* Antenatal suspicion for placenta accreta spectrum\n* History of allergic reaction to Calcium Gluconate\n* Patients with hypertensive disorder of pregnancy receiving Magnesium Sulfate for seizure prophylaxis\n* Underlying Renal Disease defined as Cr\\>1.0\n* Known underlying cardiac condition\n* Cardiac glycosides (Digoxin) within two weeks for maternal or fetal indication\n* Treatment with a calcium channel blocker medication within 24 hours of screening\n* Hypertensive disorder necessitating intravenous antihypertensive medication within 24 hours of screening\n* Emergent case where study participation could impede care (judgement of obstetrician or anesthesiologist)\n* Known hypercalcemia\n* Concurrent use of any drugs that may cause hypercalcemia including\n\n  1. Vitamin D\n  2. Vitamin A\n  3. Thiazide Diuretics\n  4. Calcipotriene\n  5. Teriparatide\n* Ceftriaxone within 48 hours of screening\n* Total Parenteral Nutrition (TPN) within 48 hours of screening\n* Known Coagulopathy International Normalized Ratio (INR) ≥ 1.5\n* Vaginal delivery","FEMALE","18 Years",{"count":58,"type":22},140,[60],"PHASE2","This research study is being done to learn what effect a single dose of calcium gluconate will have on blood loss at the time of cesarean delivery in pregnancy patients at high risk for uterine atony.",[63,29,64],"Blood Loss, Surgical","Uterine Atony",[66],"Cesarean delivery","2025-10-28",{"date":69,"type":40},"2025-10-29",{"date":71,"type":40},"2025-10-20",{"date":73,"type":22},"2026-08",{"name":75,"class":47},"University of Michigan",1,{"id":78,"slug":79,"hasResults":11,"nctId":80,"briefTitle":81,"officialTitle":82,"acronym":4,"eligibilityCriteria":83,"healthyVolunteers":11,"sex":84,"minAge":56,"maxAge":4,"enrollmentInfo":85,"targetDuration":4,"studyType":87,"phases":4,"briefSummary":88,"conditions":89,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":102},"100445183","safe-and-timely-antithrombotic-removal-star-registry-100445183","NCT05077124","Safe and Timely Antithrombotic Removal (STAR) Registry","Safe and Timely Antithrombotic Removal (STAR) Registry: International Registry on the Use of CytoSorb for Removal of Antithrombotic Agents in the Acute Hospital Setting","Inclusion Criteria:\n\n* CytoSorb utilization for antithrombotic removal\n* Informed consent for prospective registry participation\n\nExclusion Criteria:\n\n• Use of CytoSorb for purpose other than antithrombotic removal","ALL",{"count":86,"type":22},1000,"OBSERVATIONAL","This registry will capture real-world clinical use patterns and associated clinical outcomes with the use of CytoSorb for the removal of antithrombotic agents.",[90,91,63,29],"Hemorrhage, Surgical","Hemorrhage Postoperative","2025-07-15",{"date":94,"type":40},"2025-07-16",{"date":96,"type":40},"2021-09-30",{"date":98,"type":22},"2025-09-30",{"name":100,"class":101},"CytoSorbents, Inc","INDUSTRY",30]